Home DocWire Picks Rheumatology Picks

Rheumatology Picks

Risk for Rheumatoid Arthritis Reduced for Patients With T2DM

Risk for Rheumatoid Arthritis Reduced for Patients With T2DM

Adalimumab, ixekizumab, Humira® No. 1 Drug Linked to $5.1 B Increase in Medical Spending

Adalimumab Versus Biosimilar: How Do These Drugs Compare in RA, PsA, PsO?

tocilizumab, COVACTA

Arthritis Drug Tocilizumab Does Not Improve Mortality in Severe COVID-19 Pneumonia

video

Dr. Nowell Discusses Which PROs Are Most Important To Rheumatology Patients

autoimmune, tofacitinib, telemedicine, covid-19, Hydroxychloroquine, Secukinumab, interview, rheumatologists, rheumatologist, arthroplasty, arthritis, rheumatic, ixekizumab, RA, rheumatoid, FDA, Rheum Round-up: Five RA Drugs Compared, Two THA Approaches, and more

Rheum Round-up: 1 in 3 Autoimmune Pts Uncertain About Vaccine, Anakinra to Treat COVID?,...

Could Anakinra Be Used To Treat Severe COVID-19?

Could Anakinra Be Used To Treat Severe COVID-19?

1 in 3 Patients With Autoimmune Diseases Uncertain About COVID-19 Vaccine

1 in 3 Patients With Autoimmune Diseases Uncertain About COVID-19 Vaccine

Artificial Intelligence Decision Aid A Significant Benefit For Patients with OA Considering Knee Replacement

Artificial Intelligence Decision Aid A Significant Benefit For Patients with OA Considering Knee Replacement

PROs, Rheum Round-up: Abatacept vs. Other bDMARDs in RA, OA and Discrimination, and more

Rheum Round-up: Abatacept vs. Other bDMARDs in RA, OA and Discrimination, and more

Perceived Discrimination Worsens Pain, Mental Outcomes in Osteoarthritis

Perceived Discrimination Worsens Pain, Mental Outcomes in Osteoarthritis

Load more
Subscribe to RSS